The same approach is followed in a still active, not recruiting, phase 2/3 clinical trial (QUALIOR - NCT03169075) enrolling patients (phase 2, n = 120; phase 3, n = 312) with metastatic cancers, including melanoma, and receiving oral targeted therapy (i.e., tyrosine kinase, epidermal growth factor receptor [EGFR], cyclin-dependent kinases, BRAF, anaplastic lymphoma kinase [ALK], mTOR, and poly (ADP-ribose) polymerase [PARP] inhibitors). Here, ALK is linked to melanoma.